Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06556888
Recruiting Observational

Observatory of Immunological Thrombopenic Purpura in the Brest Region

NCT06556888 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2019-06-20
Last updated
2024-08-16

Condition(s) studied

Immune Thrombocytopenia

Study summary

Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with ITP agree to participate Exclusion Criteria: * Other thrombocythopenia other than ITP * Patients Under guardianship * Patients without national social security

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hematology Department - Institute of Oncology and Hematology, University Hospital of Brest Brest Brittany Region Recruiting

More University Hospital, Brest trials in France

Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease Active, not recruiting
Boarding Ring Glasses Versus Placebo Glasses or Not Glasses in the Treatment of Vestibular Neuritis Recruiting
Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism Active, not recruiting
Characterization of "Bamboo" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases (BAMBOO) Recruiting
Validation of the French Version of the QASCI in Caregivers of Patients With COPD Recruiting

Other trials for the same condition

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia Recruiting
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) Active, not recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment Recruiting
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06556888 on ClinicalTrials.gov ↗ ← All trials in France